

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

8

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1153	2006/0234912	10-16-2006	Wang et al.	
	1154	2006/0182321	08-17-2006	Hu et al.	
	1155	2006/0121038	06-08-2006	Schenk et al.	
	1160	5,472,693	12-05-1995	Gourlie et al.	
	1168	5,620,844	04-15-1997	Neurath et al.	
	1169	2009/0142270 A1	06-04-2009	Schroeter et al.	
	1170	2003/0009104 A1	01-09-2003	Hyman et al.	
	1192	7,582,733	09-01-2009	Basi et al.	
	1195	6,824,780 B1	11-30-2004	Devaux et al.	
	1196	7,147,851 B1	12-12-2006	Ponath et al	
	1197	7,112,661 B1	09-26-2006	Miller	
	1209	5,910,427	06-08-1999	Mikayama	
	1210	2007/0072307 A1	03-29-2007	Godavarti et al.	
	1211	6,432,710 B1	08-13-2002	Boss, Jr. et al.	
	1215	2009/0297511	12-03-2009	Schenk	
	1216	2009/0155256	6-18-2009	Black et al	
	1242	5,417,986	05-23-1995	Reid et al.	
	1277	2007/0196375	08-23-2007	Tobinick	
	1278	2006/019850	08-31-2006	Warne et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	1151	WO	96/39834	A1	12-19-1996			
	1152	WO	01/78777	A2	10-25-2001			
	1173	WO	97/18855	A1	05-29-1997			
	1174	WO	90/14840	A1	12-13-1990			
	1175	EP	613007	A2	02-18-1994			

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

## Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

1176	EP	616 814	A1	03-21-1994			
1177	WO	97/40147	A1	10-30-1997			
1178	WO	97/37031	A1	10/09/1997			
1179	WO	97/36601	A1	10/09/1997			
1180	WO	97/28816	A1	08-14-1997			
1181	WO	96/29421	A1	09-26-1996			
1182	WO	96/14061	A1	05-17-1996			
1183	WO	94/21288	A1	09-29-1994			
1184	WO	94/16731	A1	08-04-1994			
1185	WO	94/09823	A1	05-11-1994			
1186	WO	92/15330	A1	09-17-1992			
1187	WO	92/07944	A1	05-14-1992			
1188	WO	92/05793	A1	04-16-1992			
1189	WO	90/14837	A1	12-13-1990			
1190	WO	87/06838	A1	11-19-1987			
1206	WO	04/016282	A1	2-26-2004			
1220	WO	96/01126	A1	01-18-1996			
1221	WO	90/07861		07-26-1990			
1222	EP	1 185 298	B1	06-24-2009			
1223	WO	06/066171	A1	06-22-2006			
1224	WO	06/066049	A2	06-22-2006			
1225	WO	95/05849	A1	03-02-1995			
1227	WO	94/03208	A1	02-17-1994			
1228	WO	94/29459	A1	12-22-1994			
1236	WO	98/08098	A1	02-26-1998			
1237	WO	96/22373	A1	07-25-1996			
1238	WO	97/05164	A1	02-13-1997			
1239	WO	90/05142	A1	05-17-1990			
1240	WO	96/03144	A1	02-08-1996			
1244	WO	94/17197	A1	08-04-1994			
1249	WO	96/33739	A1	10-31-1996			
1250	WO	91/19795	A1	12-26-1991			
1251	WO	92/19267	A1	11-12-1992			
1257	WO	91/10741	A1	07-25-1991			
1258	WO	93/12227	A1	06-24-1993			

Examiner  
Signature

Date  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

62731308 v1

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

Sheet 3 of 8

	1259	WO	94/40895	A1	12-19-1996			
	1267	WO	98/39303	A1	09-11-1998			
	1270	WO	92/01059	A1	01-23-1992			
	1271	WO	10/044803	A1	04-22-2010			
	1274	WO	98/04720	A1	02-05-1998			
	1276	WO	09/052439	A2	04-23-2009			
	1285	WO	97/13855		04-17-1997			

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

Sheet 4 of 8

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1156	ALLEN et al., "Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer," Arch. Neurol., 63(10): 1475-1478 (2006), abstract only.	
	1157	MAVRAGANI et al., "A Case of Reversible Posterior Leukoencephalopathy Syndrome After Rityximab Infusion," Rheumatology, 43(11) 1450-1451 (2006).	
	1158	PCT Written Opinion of 12/22/2008 for application PCT/US2008/80370.	
	1159	PCT Search Report of 01/22/2009 for application PCT/US2008/80370.	
	1161	Wikipedia entry for Antibody, retrieved April 27, 2009 from <a href="http://en.wikipedia.org/wiki/Antibody">http://en.wikipedia.org/wiki/Antibody</a> .	
	1162	TRANG et al., "Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1A) in Metastatic Adenocarcinoma Patients," Pharmaceutical Research 7(6):587-592 (1990).	
	1163	Genbank Accession number AAA69734, Schroeder et al., "Immunoglobulin heavy chain [Homo sapiens]", Anti-DNA immunoglobulin light chain IgG [Mus musculus], 07/11/95.	
	1164	Genbank Accession number BAC01733, Akahori et al., "Immunoglobulin kappa light chain VLJ region [Homo sapiens]", 07/02/02.	
	1165	SCHROEDER et al., "Preferential Utilization of Conserved Immunoglobulin Heavy Chain Variable Gene Segments During Human Fetal Life," Immunology, 87:6146-6150 (1990).	
	1167	PADLAN et al., "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-lysozyme Complex, Immunology, 86:5938-5942 (1989).	
	1171	PANGALOS et al., "Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of $\beta$ -amyloid Peptide," Biochemical Society Transactions, 33(4):553-558 (2005).	
	1172	PRADA et al., "Antibody-Mediated Clearance of Amyloid- $\beta$ Peptide From Cerebral Amyloid Angiopathy Revealed by quantitative in Vivo Imaging," Journal of Neuroscience, 27(8):1973-1980 (2007).	
	1191	BIEWENGA et al., "Cleavage of Protein A-binding IgA1 with IgA1 Protease From Streptococcus Sanguls," Immunol Commun., 12(5):491-500 (1983), abstract only.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

1193	HOGARTH, Fc Receptors Are Major Mediators of Antibody Based Inflammation in Autoimmunity," <u>Current Opinion in Immunology</u> , 14:798-802 (2002).	
1194	Ecuadorian Search Report of 07/02/2009 for Ecuador Patent Application No. SP 03-4685.	
1198	MITCHELL et al, "Prevention of Intracerebral Hemorrhage," <u>Current Drug Targets</u> , 8(7):832-838 (2007).	
1199	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," <u>Nature</u> , 332:323-327 (1988).	
1200	HILLEN-MASKE et al., "Konichalcit", <u>Rompp Chemie Lexikon</u> , 9 <sup>th</sup> edition, pg. 2322 (1990).	
1201	MUTSCHLER et al., "Arzneimittel-Wirkungen, <u>Lehrbuch der Pharmakologie und Toxikologie</u> ," Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 6 <sup>th</sup> edition, pgs. 651-656 (1991), (German Article).	
1202	SAIDO et al., "Autolytic Transition of $\mu$ -Calpain Upon Activation as Resolved by Antibodies Distinguishing Between the Pre- and Post-Autolysis Forms," <u>J. Biochem.</u> , 111:81-86 (1992).	
1203	SOOD et al., "Synthetic Peptides: A Modern Approach to Vaccination," <u>Indian Journal of Experimental Biology</u> , 34:849-861 (1998).	
1204	BUTTINI et al., " $\beta$ -Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease," <u>The Journal of Neuroscience</u> , 25(40):9096-9101 (2005).	
1205	GOLDING et al., "Vaccine Strategies: Targeting Helper T Cell Responses," <u>Annals New York Academy of Sciences</u> , 31:126-137 (1995).	
1207	BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," <u>Eur. J. Immunol.</u> , 17:1213-1215 (1987)	
1208	GHETIE et al., "CD4 Peptide-Protein Conjugates, But Not Recombinant Human CD4, Bind to Recombinant gp120 From the Human Immunodeficiency Virus in the Presence of Serum From AIDS Patients," <u>Proc. Natl. Acad. Sci.</u> , 88:5690-5693 (1991).	
1213	PCT Search Report of 10/09/2008 for application PCT/US2008/060926.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

Sheet 6 of 8

1214	PCT International Preliminary Report on Patentability (Chapter I) of 10/20/2009 with Written Opinion of 10/03/2008 for application PCT/US2008/060926.	
1217	PCT International Preliminary Report on Patentability (Chapter I) of 02/02/2010 for application PCT/US07/09499.	
1218	AUCLAIR et al., "Effect of Active Immunization Against Oestriadiol in Developing Ram Lambs on Plasma Gonadotrophin and Testosterone Concentrations, Time of Onset of Puberty and Testicular Blood Flow," <u>Journal of Reproduction and Fertility</u> , 104:7-16 (1995).	
1219	BLACK et al., "A Single Ascending Dose Study of Banezumab, A Humanized Monoclonal Antibody to A $\beta$ , In AD," 9 <sup>th</sup> International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, 1 page (April 20, 2006). Abstract only.	
1226	JANEWAY et al., <i>Immunobiology</i> , 3 <sup>rd</sup> edition, pages 2:7, 2:9, 2:12, 8:16-8:17, 12:43 (1997).	
1229	BARELLI et al., "Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid $\beta$ Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases," <i>Molecular Medicine</i> , 3(10):695-707 (1997).	
1230	HELLMAN et al., "Allergy Vaccines – A Review of Developments," <u>Clin. Immunother.</u> , 6(2): 130-142 (Aug. 1996).	
1231	KARDANA et al., "Serum HCG $\beta$ -Core Fragment is Masked by Associated Macromolecules," <u>Journal of Clinical Endocrinology and Metabolism</u> , 71(5):1393-1395.	
1232	KOLLER et al., "Active Immunization of Mice with a A $\beta$ -Hsp70 Vaccine," <u>Neurodegenerative Diseases</u> , 1:20-28 (2004).	
1233	CHECK, "Nerve Inflammation Halts Trail for Alzheimer's Drugs," <i>Nature</i> , 415:462 (2002)	
1234	GAUTHIER et al., "Alzheimer's Disease: Current Knowledge, Management and Research," <i>Can. Med. Assoc. J.</i> , "157:1047-1052 (October 15, 1997).	
1235	HUANG et al., "Amyloid $\beta$ -Peptide Possesses a Transforming Growth Factor- $\beta$ -Activity," <u>The Journal of Biological Chemistry</u> , 273(42):27640-27644 (October 16, 1998).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

Sheet 7 of 8

1241	TAHTINEN et al., "Minimal Size of HIV-1 NEF ANTIGENIC EPITOPES RECONIZED BY HUMAN SERA," Int. Conf. AIDS June 16-21 1991, Published June 1991, abstract no. W.A. 1334.
1243	JARRETT et al., "The Carboxy Terminus of the $\beta$ Amyloid Protein is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease," <u>Biochemistry</u> , 32:4693-4697 (November 05, 1993).
1245	WELLING et al., "Choice of Peptide and Peptide Length For the Generation of Antibodies Reactive With the Intact Protein," <u>FEBS Letters</u> , 182(1):81-84 (March 1985).
1246	AGADJANYAN et al., "Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope From {beta}-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide," <u>J. Immunol.</u> , 174:1580-1586 (2005).
1247	NOVARTIS, "Novartis MF59 <sup>TM</sup> -Adjuvanted Influenza Vaccine (Fluad <sup>®</sup> ) Significantly Reduces Hospitalization in Elderly," Novartis Press Release, October 19 2007.
1248	DONNELLY, "New Developments in Adjuvants," <u>Mechanism of Ageing and Development</u> , 93:171-177 (1997).
1252	JENNINGS, "Review of Selected Adjuvants Used in Antibody Production," <u>ILAR Journal</u> , 37(3) (1995).
1253	BANDLOW et al., "Untersuchungen Zum Mechanismus Der Immunologischen Adjvanswirung des Vacciniavirus <sup>1</sup> ," <u>Archiv für due gesamte Virusfoschung</u> , 38:192-204 (1972). German article.
1254	KHAN et al., "Immunopotential and Delivery Systems for Antigens for Single-Step Immunization: Recent Trends and Progress," <u>Pharmaceutical Research</u> , 11(1):2-11 (1994).
1255	HAMILTON, "Molecular Engineering: Applications to the Clinical Laboratory," <u>Clin. Chem.</u> 39(9):1988-1997 (1993).
1256	SHEEHAN et al., "The Utilization of Individual V <sub>H</sub> Exons in the Primary Repertoire of Adult BALB/c Mice <sup>1</sup> ," <u>The Journal of Immunology</u> , 151(10):5364-5375 (November 15, 1993).
1260	HERMANSON et al., "Amino Acids as Spacers," <u>Immobilized Affinity Ligand Techniques</u> , section 3.1.1.5:150-152 (1992).

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker
Attorney Docket Number	15270J-004740US

Sheet 8 of 8

1261	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 139-195 (1988).	
1262	HUDSON et al., "Antibody as a Probe," <i>Practical Immunology</i> , Chapter 2, pages 34-85 (1989).	
1263	BEGLEY, "Delivery of Therapeutic Agents to the Central Nervous System: The Problems and the Possibilities," <i>Pharmacol. Therapy</i> , 104(1): 29-45 (Oct. 2004).	
1264	MISRA et al., "Drug Delivery to the Central Nervous System: A review," <i>J. Pharm Pharm Sci.</i> , 6(2):252-273 (May 2003). Abstract.	
1265	KALLBERG et al., "Prediction of Amyloid Fibril-Forming Proteins," <i>The Journal of Biological Chemistry</i> , 276(16):12945-12950 (April 20, 2001).	
1268	Genbank Accession number AAB35009.1, Wang et al., "Antidiotypic Ig 1F7 Light Chain Variable Region [Human, 1F7 Hybridoma Cells, Peptide Partial, 120aa]," 10/28/1995.	
1269	Genbank Accession number AAD00856.1, "Igm Heavy Chain Variable Region [Homo Sapiens]," 07/31/2001.	
1272	SAIDO et al., "Amino-and-Carboxyl-Terminal Heterogeneity of $\beta$ -Amyloid Peptides Deposited in Human Brain," <i>Neuroscience Letters</i> , 215:173-176 (August 8, 1996).	
1273	<i>Stedman's Medical Dictionary</i> , 27 <sup>th</sup> Edition, "Vaccine," page 1922, lines 1-3 (2000).	
1279	KINNECOM et al., "Course of Cerebral Amyloid Angiopathy? Related Inflation," <i>Neurology</i> , 68(17):1411-1416 (2007).	
1280	KOFKE et al., "Remifentanyl-Induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE genotype," <i>Neurosurg Anesthes Neurosci.</i> , 105(1):167-175 (2007).	
1281	PCT Written Opinion of 03/08/2009 for application PCT/US2008/80382.	
1282	PCT Search Report of 03/25/2009 for application PCT/US2008/80382.	
1283	AYLWARD et al., "Cerebellar Volume in Adults With Down Syndrome," <i>Arch Neurol.</i> , 4(2):209-212 (1997). Abstract only.	
1284	HOLM et al., "Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1," <i>Mol. Immunol.</i> , 44(6):1075-1084 (Feb 2007).	

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1